title: Venous thromboprophylaxis in UK medical inpatients.
abstract: We prospectively assessed the implementation of venous thromboembolism (VTE) prophylaxis guidelines and the impact of grand round presentation of the data in changing clinical practice. Two NHS teaching hospitals were studied for 24 months from January 2003. Patients were risk stratified according to the THRIFT (thromboembolic risk factor) consensus group guidelines and compared with the recommendations of the THRIFT and ACCP (American College of Chest Physicians) consensus groups. Six months following presentation of the initial results, a further analysis was made to assess changes in clinical practice. 1128 patients were assessed of whom 1062 satisfied the inclusion criteria for thromboprophylaxis. 89% of all patients were stratified as having high or moderate risk of developing VTE. Of these only 28% were prescribed some form of thromboprophylaxis-4% received the THRIFT-recommended and 22% received the ACCP-recommended thromboprophylaxis. The vast majority (72%) received no thromboprophylaxis at all. Reassessment, following data presentation at grand rounds, showed a significant increase to 31% inpatients receiving THRIFT (P<0.0001) and ACCP (P=0.002) recommended thromboprophylaxis. However,the proportion of patients receiving no form of prophylaxis barely changed (72% to 69%: P=0.59). We found a gross underutilization of thromboprophylaxis in hospitalized medical patients. A simple grand-round presentation of the data and recommended guidelines to clinicians significantly increased the proportion of patients receiving recommended thromboprophylaxis but did not increase the overall proportion of patients receiving it. We therefore conclude that a single presentation of guidelines is not enough to achieve the desired levels. Such presentations may only serve to make DVT (deep venous thromboembolism) aware clinicians prescribe prophylaxis more accurately.
authors.affiliation: Department of Medicine, St James University Hospital NHS trust, Beckett Street, Leeds, UK.
authors.forename: S T
authors.initials: ST
authors.lastname: Rashid
authors.forename: M R
authors.initials: MR
authors.lastname: Thursz
authors.forename: N A
authors.initials: NA
authors.lastname: Razvi
authors.forename: R
authors.initials: R
authors.lastname: Voller
authors.forename: T
authors.initials: T
authors.lastname: Orchard
authors.forename: S T
authors.initials: ST
authors.lastname: Rashid
authors.forename: A A
authors.initials: AA
authors.lastname: Shlebak
mesh_terms: D000208:Acute Disease; D000925:Anticoagulants / Q000627:therapeutic use*; D001458:Bandages; D003362:Cost-Benefit Analysis; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006760:Hospitalization; D006784:Hospitals, Teaching; D006801:Humans; D017410:Practice Guidelines as Topic; D011446:Prospective Studies; D012307:Risk Factors; D013923:Thromboembolism / Q000517:prevention & control*; D020246:Venous Thrombosis / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight